US Bankruptcy Chapter 11 Insolvency SEC Filings — September 21, 2026

Sale of ST-920 to PTC Therapeutics for $111M cash upfront + $100M milestones confirms asset monetization at a fraction of prior valuations; stock delisted to OTC Pink (SGMOQ) — equity holders face near-total loss

Court-approved sale (Docket No. 426) on September 2, 2026, with bid deadline August 4 and auction August 10 — process was competitive but final price suggests limited bidding interest

No insider transactions filed post-bankruptcy — management likely restricted from trading, signaling no conviction signal available

No forward-looking guidance or capital allocation actions (dividends, buybacks) — company is in wind-down mode, not operating as a going concern

Chapter 11 case (No. 26-10989) in Delaware — a favorable jurisdiction for debtors, but no DIP financing or restructuring plan disclosed, suggesting liquidation path

The $111M upfront is a small fraction of the estimated $500M+ invested in ST-920 development — implies severe value destruction for pre-bankruptcy investors

No operational metrics or financial ratios available — company ceased reporting post-delisting, creating information asymmetry for OTC traders

The sale to PTC Therapeutics provides a potential floor for creditor recoveries but zero recovery for common equity holders — trade SGMOQ only as a speculative lottery ticket

Stock delisted to OTC Pink (SGMOQ) with no operating business remaining — equity holders likely receive zero distribution from bankruptcy estate

No DIP financing or working capital disclosed — company may have insufficient funds to complete bankruptcy administration, risking conversion to Chapter 7

No ongoing SEC reporting obligations post-delisting — investors have no visibility into creditor claims, administrative costs, or distribution timeline

The $100M milestone payments are contingent on PTC achieving regulatory and sales targets — unlikely to materialize in time to benefit current creditors

Creditors or equity holders could challenge the sale process as inadequate — potential for litigation delaying distributions

No scheduled events (earnings calls, AGMs, record dates) — zero near-term catalysts for the stock, only negative drift

OTC Pink stocks typically have wide bid-ask spreads and low volume — exiting positions will be costly or impossible

This sale may set a low valuation benchmark for other distressed gene therapy assets — negative read-through for peers like Bluebird Bio or uniQure

For sophisticated distressed investors, the company's debt instruments (if any) may trade at deep discounts with potential recovery from the $111M cash — requires analysis of capital structure

If PTC Therapeutics successfully develops and commercializes ST-920, the $100M milestones could provide additional recovery for creditors — monitor PTC's pipeline progress

Sangamo may have significant net operating loss (NOL) carryforwards that could be valuable to a buyer in a Section 363 sale or plan of reorganization — potential hidden value

OTC Pink stocks with low float and high short interest can experience violent squeezes — SGMOQ may see speculative trading if bankruptcy news generates retail interest

PTC acquired ST-920 at a distressed price — if the therapy succeeds, this could be a highly accretive deal for PTC shareholders

The Sangamo process provides a playbook for other cash-strapped gene therapy firms — investors can identify similar companies with valuable assets but poor balance sheets for pre-bankruptcy positioning

Large creditors may have influence over the bankruptcy process — active participation could improve recovery outcomes [OPPORTUNITY for institutional investors]

Sangamo's Chapter 11 highlights the ongoing cash burn crisis in the gene therapy sector, where high R&D costs and regulatory hurdles are forcing asset sales at distressed valuations — expect more filings from peers with similar profiles

PTC Therapeutics' acquisition of ST-920 at a fraction of development cost exemplifies how larger biopharma companies are using bankruptcy proceedings to acquire de-risked assets cheaply — watch for similar opportunistic M&A

The delisting of Sangamo to the OTC Pink Market (SGMOQ) is a reminder that post-bankruptcy equities often trade with zero fundamental support — retail investors should avoid these names unless they have a specific distressed thesis

Sangamo's filing in Delaware (Case No. 26-10989) continues the trend of companies choosing Delaware for its predictable and debtor-friendly legal framework — this jurisdiction remains the default for complex Chapter 11 cases

The absence of insider trading in Sangamo's filing is itself a signal — management is likely restricted and has no personal capital at risk, indicating no confidence in equity recovery

Monitor Delaware Bankruptcy Court docket (Case No. 26-10989) for plan of reorganization, creditor claims bar date, and any objections to the sale — key events will determine distribution timeline

Watch for PTC's regulatory filings and clinical updates on ST-920 — positive data could trigger milestone payments and increase creditor recovery

Monitor SGMOQ trading volume and price action — any spike could indicate speculative interest or insider buying (if permitted)

Watch Bluebird Bio, uniQure, and Voyager Therapeutics for similar cash crunch warnings — Sangamo's fate may be a leading indicator

Any rulings on sale objections or fee applications in Sangamo's case could set precedents for future gene therapy bankruptcies

Watch for the company to file Form 15 to terminate SEC registration — this would further reduce transparency and signal final wind-down

The timing and amount of any distribution to creditors (especially unsecured) will determine if there is any residual value for equity — likely 12-18 months out